AbbVie tells USTR Germany drug pricing reforms cut innovative medicine value by nearly 54%

Bitget2026/09/22 16:23

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AbbVie testified in a USTR Section 301 probe into Germany, arguing drug pricing and reimbursement policies undermine innovation and harm U.S. commerce.
Executive Vice President Perry Siatis said Germany’s approach systematically undervalues transformative medicines, risking future investment in next-generation treatments.
AbbVie cited reforms that lifted mandatory manufacturer rebates to 15.5% from 7%, citing cumulative measures that can cut an innovative medicine’s value by nearly 54%.
Company framed Germany as a wealthy market contributing less to global R&D costs, shifting the burden to the U.S. healthcare system.
AbbVie said it is seeking a “constructive path forward” aimed at more equitable investment by wealthy countries in pharmaceutical innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AbbVie tells USTR Germany drug pricing reforms cut innovative medicine value by nearly 54%

You may also like

Crypto prices